NEW YORK, Sept 28 (Reuters) - Drugmaker Merck & Co
MRK.N said on Wednesday that it agreed to allow China's
Sinopharm 1099.HK to distribute and import its COVID-19
antiviral molnupiravir in China if the drug is approved for use
there.
The drugmaker said in a statement that it reached a
cooperation framework agreement with Sinopharm that grants the
Chinese company distribution and exclusive import rights of the
medicine in the China mainland market.
Merck also said it will allow China National Biotec Group,
an affiliate of Sinopharm, to make the drug in China and has
agreed to transfer technology to help with that production.
Molnupiravir is sold under the brand name Lagevrio in the
U.S. Merck developed the pill - and shares the profits equally -
with partner Ridgeback Biotherapeutics.
The antiviral pill was once touted as a potential game
changer for treating COVID-19, but Paxlovid, a rival drug made
by Pfizer Inc PFE.N , had significantly better results in its
clinical trial and has been much more widely used in the United
States.
(Reporting by Michael Erman; editing by Jonathan Oatis)
((michael.erman@thomsonreuters.com;))